Edition:
India

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

87.20EUR
17 Jun 2019
Change (% chg)

-- (--)
Prev Close
€87.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
143,405
52-wk High
€124.90
52-wk Low
€76.45

Latest Key Developments (Source: Significant Developments)

Morphosys's Licensee Janssen Announces Phase 3 Results For Guselkumab
Friday, 14 Jun 2019 

June 14 (Reuters) - MORPHOSYS AG ::MORPHOSYS'S LICENSEE JANSSEN ANNOUNCES TOP-LINE PHASE 3 RESULTS FOR GUSELKUMAB (TREMFYA(R)) IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS.ACCORDING TO JANSSEN, BOTH STUDIES MET THEIR PRIMARY ENDPOINTS.DATA WILL SERVE AS BASIS OF SUBMISSIONS FOR APPROVAL OF GUSELKUMAB AS A TREATMENT FOR PSORIATIC ARTHRITIS, WHICH ARE ANTICIPATED FOR LATER THIS YEAR.  Full Article

Morphosys Q1 net loss widens to 22.7 million euros
Wednesday, 8 May 2019 

May 7 (Reuters) - MorphoSys AG ::SAYS MOR208: ROLLING SUBMISSION OF L-MIND STUDY DATA TO FDA TO SUPPORT POTENTIAL APPROVAL IN U.S. ON TRACK.SAYS DAVID TREXLER HIRED AS PRESIDENT, MORPHOSYS US INC.; BUILD-UP OF COMMERCIAL CAPABILITIES ONGOING.SAYS MOR208: INTERACTIONS WITH EUROPEAN REGULATORY AUTHORITIES TO EXPLORE USE OF L-MIND AS BASIS FOR A SUBMISSION OF A POTENTIAL MARKETING AUTHORIZATION APPLICATION IN EUROPE ONGOING.SAYS MOR202: PIVOTAL PHASE 2 STUDY IN THIRD LINE AND PHASE 3 STUDY IN SECOND LINE MULTIPLE MYELOMA STARTED BY PARTNER I-MAB IN TAIWAN.SAYS TREMFYA(R): CLINICAL DEVELOPMENT EXPANDED TO INCLUDE ULCERATIVE COLITIS (UC) AND FAMILIAL ADENOMATOUS POLYPOSIS (FAP).SAYS MOR106: START OF PHASE 2 GECKO TRIAL WITH MOR106 AND TOPICAL CORTICOSTEROIDS UNDER AGREEMENT WITH NOVARTIS.SAYS FINANCIAL GUIDANCE FOR 2019 REAFFIRMED.SAYS GROUP REVENUES ROSE TO EUR 13.5 MILLION, COMPARED TO EUR 2.8 MILLION IN Q1 OF 2018.SAYS EARNINGS BEFORE INTEREST AND TAXES (EBIT) AMOUNTED TO EUR -23.6 MILLION IN Q1 OF 2019 (Q1 2018: EUR -19.0 MILLION.SAYS IN Q1 2019, CONSOLIDATED NET LOSS AMOUNTED TO EUR -22.7 MILLION (Q1 2018: EUR -19.5 MILLION). LOSS PER SHARE FOR Q1 OF 2019 WAS EUR -0.72 (Q1 2018: EUR -0.67).  Full Article

Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study
Wednesday, 24 Apr 2019 

April 24 (Reuters) - GALAPAGOS NV ::ANNOUNCED ON TUESDAY INITIATION OF GECKO.GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.RECRUITMENT WILL TAKE PLACE IN THE U.S. AND CANADA.STUDY IS INTENDED TO SERVE AS AN IND (INVESTIGATIONAL NEW DRUG) OPENER WITH THE U.S. FDA.  Full Article

Morphosys Says CEO Simon Moroney To Retire
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - MorphoSys AG ::SIMON MORONEY, CEO AND CO-FOUNDER OF MORPHOSYS, ANNOUNCES HIS INTENTION TO RETIRE.MORONEY WILL STEP DOWN AS CEO ON EXPIRY OF HIS CURRENT CONTRACT ON JUNE 30, 2020, OR WHEN A SUCCESSOR IS APPOINTED, WHICHEVER COMES SOONER.  Full Article

Morphosys Announces Appointment Of David Trexler As President
Wednesday, 6 Feb 2019 

Feb 5 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES APPOINTMENT OF DAVID TREXLER AS PRESIDENT AND MEMBER OF THE BOARD OF DIRECTORS OF MORPHOSYS US INC..MORPHOSYS AG SAYS APPOINTMENT OF DAVID R. TREXLER AS PRESIDENT AND MEMBER OF BOARD OF DIRECTORS OF MORPHOSYS US INC., EFFECTIVE FEBRUARY 6, 2019.  Full Article

Morphosys AG Announces Third Quarter 2018 Results
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - MorphoSys AG ::MORPHOSYS AG ANNOUNCES THIRD QUARTER 2018 RESULTS.Q3 REVENUE 55 MILLION EUR VERSUS 15 MILLION EUR YEAR AGO.CASH POSITION OF EUR 481.2 MILLION AS OF SEPTEMBER 30, 2018.CONFIRMS ITS 2018 FINANCIAL GUIDANCE WHICH HAD BEEN INCREASED AFTER SIGNING AN AGREEMENT WITH NOVARTIS FOR MOR106 IN JULY 2018.MORPHOSYS EXPECTS REVENUES ON UPPER END OF GUIDED RANGE FROM EUR 67 MILLION TO EUR 72 MILLION FOR 2018.  Full Article

Morphosys And Galapagos Announce U.S. Antitrust Clearance For Global License Agreement For Mor106 With Pharma Partner
Thursday, 13 Sep 2018 

Sept 12 (Reuters) - :MORPHOSYS AND GALAPAGOS ANNOUNCE U.S. ANTITRUST CLEARANCE FOR GLOBAL LICENSE AGREEMENT FOR MOR106 WITH PHARMA PARTNER.MORPHOSYS AG-FOLLOWING U.S. ANTITRUST CLEARANCE, MORPHOSYS CONFIRMS INCREASE OF ITS FINANCIAL GUIDANCE AS ALREADY COMMUNICATED ON JULY 19, 2018.  Full Article

Morphosys AG Announces Appointment Of Jennifer Herron As President Of Morphosys Us Inc
Wednesday, 25 Jul 2018 

July 24 (Reuters) - MorphoSys AG ::ANNOUNCES APPOINTMENT OF JENNIFER HERRON AS PRESIDENT OF MORPHOSYS US INC. AND EXECUTIVE VICE PRESIDENT, GLOBAL COMMERCIAL.HERRON WAS ALSO APPOINTED AS MEMBER OF THE BOARD OF DIRECTORS OF MORPHOSYS US INC.  Full Article

Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing
Monday, 9 Apr 2018 

April 9 (Reuters) - MorphoSys AG ::MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING .MORPHOSYS AG SAYS OFFERING 8.3 MILLION ADSS, ASSUMING PUBLIC OFFERING PRICE OF $24.12 PER ADS.  Full Article

Morphosys Says Tremfya Approved To Treat Psoriasis In Japan
Friday, 6 Apr 2018 

April 6 (Reuters) - MorphoSys AG ::SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN.  Full Article

German stocks - Factors to watch on May 22

BERLIN/FRANKFURT, May 22 The following are some of the factors that may move German stocks on Wednesday: